Gastroparesis and Delayed Gastric Emptying
Tirzepatide slows gastric emptying as a pharmacological consequence of GLP-1 receptor activation (a class effect). This contributes to early satiety and appetite suppression but also to nausea, vomiting, and the risk of food residue aspiration during general anaesthesia. In patients with pre-existing diabetic gastroparesis (delayed gastric emptying from autonomic neuropathy — a complication of long-standing T2D), tirzepatide may worsen symptoms significantly.
A review of GLP-1 RA and tirzepatide effects on gastric emptying (PMID 39418085) noted that delayed gastric emptying creates aspiration risk for surgery patients on these agents. Current anaesthetic guidelines in several countries now recommend stopping GLP-1 RAs (and by extension, tirzepatide) before elective surgery, though protocols vary by institution and drug half-life. Tirzepatide’s once-weekly dosing means complete clearance takes several weeks.
Real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS, PMID 39141075) found tirzepatide’s overall GI safety profile was similar to GLP-1 RAs, with no significantly increased risk of diabetic retinopathy or pancreato-biliary adverse events compared to GLP-1 RAs. This provides some reassurance, but pharmacovigilance data are subject to reporting biases.
Ontology Gastroparesis and Delayed Gastric Emptying [warns_about] Tirzepatide Gastroparesis and Delayed Gastric Emptying [relates] GLP-1 Receptor Agonism Gastroparesis and Delayed Gastric Emptying [relates] Nausea and Vomiting Risk
Numbers
- Clinical gastroparesis rates: Not separately reported in SURPASS trials (no absolute rates)
- Gastric emptying slowing: Pharmacological effect confirmed; not quantified as separate AE
- FAERS comparison: GI safety profile comparable to GLP-1 RAs (PMID 39141075)
Practical Interpretation
- Who appears most at risk: Patients with pre-existing gastroparesis; patients undergoing surgery (aspiration risk); patients with long diabetes duration and autonomic neuropathy
- Severity: Potentially serious for surgical patients; quality-of-life impact for patients with severe delayed emptying
- Mitigation: Screen for gastroparesis before starting; hold before elective surgery (consult anaesthetic guidance); use prokinetics with caution; start at lowest dose
Connections
- Tirzepatide — warns_about
- GLP-1 Receptor Agonism — may_explain (mechanism)
- Nausea and Vomiting Risk — relates